The innovator’s award recognises Josef Penninger’s work in identifying a key molecular pathway how hormone replacement therapies and contraceptive pills can lead to breast cancer. His team provided the first genetic proof that a protein called RANKL is the master regulator of bone loss, which has contributed to the development of a novel drug already approved for the treatment of osteoporosis and skeletal related events in multiple cancers.
He was also the first to discover that RANKL not only regulates bone loss but is absolutely essential to enable sex hormone driven lactation in pregnant females, a finding that could explain further the connection between sex hormones and bone loss. Based on these groundbreaking findings, Penninger’s group went on to show that RANKL is indeed a missing link between sex hormones, in particular the sex hormone progesterone, and breast cancer, leading to the hypothesis that RANKL is a key driver of breast cancer initiation.
In addition, Penninger’s group has developed entirely novel genetics tools, so-called haploid stem cells, to quickly assess the function of specific genes that cause breast cancer and help tumours to spread. “This is the next step in the post genome era of cancer”, says Prof Josef Penninger. “We will use our new technologies to rapidly check the function of hundreds or even thousands of human breast cancer gene candidates”. The Austrian researchers expect to verify new breast cancer pathways, which they hope will quickly lead to a major impact in preventing and treating the disease.
Supported by the $7.4 million award, Josef Penninger intends to further use this knowledge to develop a new diagnostic method that helps in making predictions concerning the chances that any patient will develop breast cancer. At risk patients will then be able to start preventative treatment using the existing RANK ligand-blocking medicines. Josef Penninger adds: “If our experimental data could be extrapolated to humans, which is what we strongly believe, then we might have an entirely novel way of early breast cancer detection and, since RANKL inhibition is already used in patients, we even would have a medicine within immediate reach that could be used to possibly prevent the disease in those women at high risk”.
The Institute of Molecular Biotechnology (IMBA) combines fundamental and applied research in the field of biomedicine. Interdisciplinary research groups address functional genetic questions, particularly those related to the origin of disease. IMBA is a subsidiary of the Austrian Academy of Sciences, the leading organization promoting non-university academic basic research in Austria. Earlier this year IMBA was voted as second to top international workplace for postdoctoral researchers, by readers of the US based and online life sciences magazine, The Scientist.
Phone: +43 1 79730 3626
Schramek et al. (2010). Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature. 468(7320):98-102
IMBA press release from 2010: „Researchers find how HRT and the Pill can lead to breast cancer and suggest possible treatment“
Josef Penninger was awarded with the Innovator Award for his project “Novel Approaches to Breast Cancer Prevention and Inhibition of Metastases” (contract number W81XWH-12-1-0093) through the US Department of Defense. Congressionally Directed Medical Research Program: http://cdmrp.army.mil/bcrp/
More articles from Awards Funding:
Open call for applications for the Innovation Award Laser Technology 2014
12.06.2013 | Fraunhofer-Institut für Lasertechnik ILT
Fraunhofer IIS researchers receive Joseph von Fraunhofer Prize for 3D Hall sensor
11.06.2013 | Fraunhofer-Institut für Integrierte Schaltungen IIS
- Biological fermentation process converts CO and CO2 into bioethanol and platform chemicals
- Process uses energy contained in steel plant off-gases
- Ten-year co-operation to develop and market integrated environmental solutions for the steel industry worldwide
Siemens Metals Technologies and LanzaTech have signed a ten-year co-operation agreement to develop and market integrated environmental solutions for the steel industry worldwide. The collaboration will utilize the ground-breaking fermentation technology developed by LanzaTech transforming carbon-rich off-gases generated by the steel industry into low carbon bioethanol and other platform chemicals. ...
Novel application of 3D printing could enable the development of miniaturized medical implants, compact electronics, tiny robots, and more
3D printing can now be used to print lithium-ion microbatteries the size of a grain of sand. The printed microbatteries could supply electricity to tiny devices in fields from medicine to communications, including many that have lingered on lab benches for lack of a battery small enough to fit the ...
... two engines aircraft project “Elektro E6”.
The countdown has been started for opening the gates again for the worldwide leading aviation and space event in Le Bourget, Paris from June 17th - 23rd, 2013.
EADCO & PC-Aero will present at the Paris Air Show in Hall H4 booth F-7 their new future aircraft and innovative project: ...
Siemens scientists have developed new kinds of ceramics in which they can embed transformers.
The new development allows power supply transformers to be reduced to one fifth of their current size so that the normally separate switched-mode power supply units of light-emitting diodes can be integrated into the module's heat sink.
The new technology was developed in cooperation with industrial and research partners who ...
Cheaper clean-energy technologies could be made possible thanks to a new discovery.
Led by Raymond Schaak, a professor of chemistry at Penn State University, research team members have found that an important chemical reaction that generates hydrogen from water is effectively triggered -- or catalyzed -- by a nanoparticle composed of nickel and phosphorus, two inexpensive elements that are abundant on Earth. ...
19.06.2013 | Life Sciences
19.06.2013 | Agricultural and Forestry Science
19.06.2013 | Studies and Analyses
14.06.2013 | Event News
13.06.2013 | Event News
10.06.2013 | Event News